Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy

Kudo,Masashi; Kudo,Masashi; Ishii,Genichiro; Ishii,Genichiro; Gotohda,Naoto; Gotohda,Naoto; Konishi,Masaru; Konishi,Masaru; Takahashi,Shinichiro; Takahashi,Shinichiro; Kobayashi,Shin; Kobayashi,Shin; Sugimoto,Motokazu; Sugimoto,Motokazu; Martin,John D.; Martin,John D.; Cabral,Horacio; Cabral,Horacio; Kojima,Motohiro; Kojima,Motohiro

doi:10.3892/or.2022.8332

Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy

Authors:
- Masashi Kudo
- Genichiro Ishii
- Naoto Gotohda
- Masaru Konishi
- Shinichiro Takahashi
- Shin Kobayashi
- Motokazu Sugimoto
- John D. Martin
- Horacio Cabral
- Motohiro Kojima
View Affiliations

Affiliations: Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba 277‑8577, Japan, Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba 277‑8577, Japan, NanoCarrier Co., Ltd. Kashiwa, Chiba 277‑0882, Japan, Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo 113‑8656, Japan
Published online on: May 17, 2022 https://doi.org/10.3892/or.2022.8332
Article Number: 121
Copyright: © Kudo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The pathological prognostic factors in pancreatic cancer patients who have received neoadjuvant therapy (NAT) are still elusive. The aim of the present study was to investigate the prognostic potential of histological tumor necrosis (HTN) in patients who received NAT and to evaluate tumor changes after NAT. HTN was studied in 44 pancreatic cancer patients who received NAT followed by surgery (NAT group) compared with 263 patients who received upfront surgery (UFS group). The prognostic factors in the NAT group were analyzed, and carbonic anhydrase 9 (CA‑9) expression was compared between the NAT and USF group to evaluate the hypoxic microenvironment changes during NAT. HTN was found in 15 of 44 patients in the NAT group, and its frequency was lower than that in the UFS group (34 vs. 51%, P=0.04). Cox proportional hazards models identified HTN as an independent risk factor for relapse‑free survival in the NAT group [risk ratio (RR), 5.60; 95% confidence interval (CI): 2.27‑14.26, P<0.01]. Significant correlations were found between HTN and CA‑9 expression both in the NAT and UFS groups (P<0.01 for both). CA‑9 expression was significantly upregulated in the NAT group overall, although this upregulation was specifically induced in patients without HTN. In conclusion, HTN was a poor prognostic factor in pancreatic cancer patients receiving NAT followed by surgery, and the present study suggests a close association between HTN and tumor hypoxia. Increased hypoxia after NAT may support the thesis for re‑engineering the hypoxia‑alleviating tumor microenvironment in NAT regimens for pancreatic cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Zhan HX, Xu JW, Wu D, Wu ZY, Wang L, Hu SY and Zhang GY: Neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of prospective studies. Cancer Med. 6:1201–1219. 2017. View Article : Google Scholar : PubMed/NCBI
3	Sugimoto M, Takahashi N, Farnell MB, Smyrk TC, Truty MJ, Nagorney DM, Smoot RL, Chari ST, Carter RE and Kendrick ML: Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. J Surg Oncol. 120:976–984. 2019. View Article : Google Scholar
4	Unno M, Hata T and Motoi F: Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: A meta-analysis of comparative studies by intention-to-treat analysis. Surg Today. 49:295–299. 2019. View Article : Google Scholar : PubMed/NCBI
5	Kudo M, Kobayashi T, Gotohda N, Konishi M, Takahashi S, Kobayashi S, Sugimoto M, Okubo S, Martin J, Cabral H, et al: Clinical utility of histological and radiological evaluations of tumor necrosis for predicting prognosis in pancreatic cancer. Pancreas. 49:634–641. 2020. View Article : Google Scholar : PubMed/NCBI
6	Mitsunaga S, Hasebe T, Iwasaki M, Kinoshita T, Ochiai A and Shimizu N: Important prognostic histological parameters for patients with invasive ductal carcinoma of the pancreas. Cancer Sci. 96:858–865. 2005. View Article : Google Scholar
7	Hiraoka N, Ino Y, Sekine S, Tsuda H, Shimada K, Kosuge T, Zavada J, Yoshida M, Yamada K, Koyama T and Kanai Y: Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer. 103:1057–1065. 2010. View Article : Google Scholar : PubMed/NCBI
8	Okusaka T, Nakamura M, Yoshida M, Kitano M, Uesaka K, Ito Y, Furuse J, Hanada K and Okazaki K: Clinical practice guidelines for pancreatic cancer 2019 from the Japan Pancreas Society: A synopsis. Pancreas. 49:326–335. 2020. View Article : Google Scholar : PubMed/NCBI
9	Takahashi S: How to treat borderline resectable pancreatic cancer: Current challenges and future directions. Jpn J Clin Oncol. 48:205–213. 2018. View Article : Google Scholar
10	Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, et al: Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 49:190–194. 2019. View Article : Google Scholar
11	Takahashi S, Ohno I, Ikeda M, Kobayashi T, Akimoto T, Kojima M, Konishi M and Uesaka K: Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: Study protocol for an open-label, multicentre, prospective phase II trial (JASPAC05). BMJ Open. 7:e0184452017.PubMed/NCBI
12	Takahashi S, Ohno I, Ikeda M, Konishi M, Kobayashi T, Akimoto T, Kojima M, Morinaga S, Toyama H, Shimizu Y, et al: Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: A phase II open-label multicenter prospective trial (JASPAC05). Ann Surg. Oct 15–2020.(Epub ahead of print). doi: 10.1097/SLA.0000000000004535. View Article : Google Scholar
13	Okubo S, Kojima M, Matsuda Y, Hioki M, Shimizu Y, Toyama H, Morinaga S, Gotohda N, Uesaka K, Ishii G, et al: Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. Sci Rep. 9:171452019. View Article : Google Scholar : PubMed/NCBI
14	Brierley JD, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumours. John Wiley and Sons; 2017
15	N Kalimuthu S, Serra S, Dhani N, Hafezi-Bakhtiari S, Szentgyorgyi E, Vajpeyi R and Chetty R: Regression grading in neoadjuvant treated pancreatic cancer: An interobserver study. J Clin Pathol. 70:237–243. 2017. View Article : Google Scholar
16	Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ and Ames FC: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339. 1992. View Article : Google Scholar : PubMed/NCBI
17	Aperio Positive Pixel Count Algorithm. Journal. 2020.
18	Mirkin KA, Greenleaf EK, Hollenbeak CS and Wong J: Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer. Int J Surg. 52:221–228. 2018. View Article : Google Scholar : PubMed/NCBI
19	Sakuyama N, Kojima M, Kawano S, Matsuda Y, Mino-Kenudson M, Ochiai A and Ito M: Area of residual tumor is a robust prognostic marker for patients with rectal cancer undergoing preoperative therapy. Cancer Sci. 109:871–878. 2018. View Article : Google Scholar
20	Kawai M, Hirono S, Okada KI, Miyazawa M, Shimizu A, Kitahata Y, Kobayashi R, Ueno M, Hayami S, Tanioka K and Yamaue H: Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. Surgery. 165:1151–1160. 2019. View Article : Google Scholar : PubMed/NCBI
21	Lei MZ, Li XX, Zhang Y, Li JT, Zhang F, Wang YP, Yin M, Qu J and Lei QY: Acetylation promotes BCAT2 degradation to suppress BCAA catabolism and pancreatic cancer growth. Signal Transduct Target Ther. 5:702020. View Article : Google Scholar : PubMed/NCBI
22	Zheng Y, Wu C, Yang J, Zhao Y, Jia H, Xue M, Xu D, Yang F, Fu D, Wang C, et al: Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer. Signal Transduct Target Ther. 5:532020. View Article : Google Scholar : PubMed/NCBI
23	Arora S, Bhardwaj A, Singh S, Srivastava SK, McClellan S, Nirodi CS, Piazza GA, Grizzle WE, Owen LB and Singh AP: An undesired effect of chemotherapy: Gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4. J Biol Chem. 288:21197–21207. 2013. View Article : Google Scholar : PubMed/NCBI
24	Däster S, Amatruda N, Calabrese D, Ivanek R, Turrini E, Droeser RA, Zajac P, Fimognari C, Spagnoli GC, Iezzi G, et al: Induction of hypoxia and necrosis in multicellular tumor spheroids is associated with resistance to chemotherapy treatment. Oncotarget. 8:1725–1736. 2017. View Article : Google Scholar
25	Hoang NT, Kadonosono T, Kuchimaru T and Kizaka-Kondoh S: Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model. Cancer Sci. 107:1151–1158. 2016. View Article : Google Scholar
26	Shannon AM, Bouchier-Hayes DJ, Condron CM and Toomey D: Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev. 29:297–307. 2003. View Article : Google Scholar : PubMed/NCBI
27	Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, Stylianopoulos T, Mousa AS, Han X, Adstamongkonkul P, et al: Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 4:25162013. View Article : Google Scholar : PubMed/NCBI